Navigation Links
Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimer's Association International Conference on Alzheimer's Disease
Date:7/8/2010

ties.  As AD progresses, individuals may also experience changes in personality and behavior, such as anxiety, agitation, delusions or hallucinations. AD and other dementias currently affect an estimated 35.6 million people worldwide, a number that is expected to double every 20 years, to 65.7 million in 2030.(1)  In the United States alone, the disease is so prevalent that every 70 seconds someone is diagnosed with AD.(2)  AD not only places a tremendous burden on patients, but also on those caring for them, and global healthcare systems.  The total worldwide societal cost for AD and other dementias is estimated at $422 billion in 2009, with U.S. specific costs estimated at $97 billion.(3)

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 The Chinese wound care market is ... in the incidence of lifestyle diseases, coupled with the ... of better quality of wound care products provide the ... of public health insurance schemes and increased reimbursement rate ... on the findings of primary and secondary researches, this ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
(Date:9/30/2014)... Calif. , Sept. 30, 2014 ... of the American Association of Tissue Banks (AATB), ... , Chief Executive Officer. Accreditation follows ... by a specially trained AATB inspector.  It establishes ... performance within the facility meets or exceeds the ...
Breaking Medicine Technology:China Wound Care Market 2China Wound Care Market 3Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Biostructures, LLC Earns AATB Accreditation 2
... 2007 - Late-breaking Phase III,clinical trial data ... Thrombosis and Haemostasis (ISTH) Congress demonstrate,that once-daily ... venous thromboembolism (VTE) in patients undergoing,knee replacement ... current standard of care. Patients in the ...
... with Positive Phase IIa Clinical,Trial Results, First ... Key,Product in AM-Pharma's Pipeline , BUNNIK, The ... developing novel therapeutics to treat,infectious and inflammatory ... its Phase IIa Alkaline Phosphatase (AP) trial,for ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 2AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 3AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 4AM-Pharma Announces Positive Results of Phase IIa Clinical Trial,with Alkaline Phosphatase For Ulcerative Colitis 5
(Date:10/1/2014)... October 01, 2014 Two bicyclists began ... them across the country in an effort to raise ... families. The cyclists, a father-daughter team, plan to ... in Blaine, Washington and finishing in Key West Florida. ... For The Warriors®, a national nonprofit organization that assists ...
(Date:10/1/2014)... Long-acting insulin is safer and more effective than ... according to new research published in the ... and twice-daily doses of both long- and intermediate-acting ... , "In patients with Type 1 diabetes, we ... insulin when it came to controlling blood sugar, ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Indosoft, Inc., a ... Q-Suite, announces that it has added support for Sangoma ... Sangoma and Indosoft have a history of bringing ... Sangoma's patent-pending technology offers a significant benefit to those using ... that is now available to users of Q-Suite. , In ...
(Date:10/1/2014)... October 01, 2014 Nearly a year-and-a-half ... Pueblo County District Court jury awarded him $4.75 million; ... 61 years old. Casper had been too sick ... , According to the Court Documents (District Court, Pueblo ... BPH, a benign non-cancerous condition of his prostate, when ...
(Date:9/30/2014)... Thompson HealthDay Reporter TUESDAY, ... of Ebola has surfaced in the United States, involving a ... announced late Tuesday. The critically ill patient, being cared ... been diagnosed with the deadly virus, officials from the U.S. ... afternoon news conference. The man is receiving intensive care ...
Breaking Medicine News(10 mins):Health News:Father-Daughter Cycling Duo to Ride Cross-Country to Benefit Hope For The Warriors 2Health News:Long-acting insulin is safer, more effective for patients with Type 1 diabetes 2Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 2Health News:Law Offices of D.R. Jones Client Wins 4.7 Million Dollar Verdict, Insurance Company Files Motion for a New Trial 3Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 2Health News:CDC Confirms First Patient Diagnosed With Ebola in United States 3
... ... helicopter, DENVER, Oct. 27 ... in the,world, today announced its Products Division has been awarded a contract ... Black Hawk Multi-Mission Medevac Interior Systems. Production has,started and is anticipated to ...
... Journal of Neurodevelopmental Disorders to complement its ... will be available in both online and print ... include both researchers and clinicians interested in an ... of neurodevelopmental disorders. , The Journal of ...
... people who have a positive outlook, lower stress levels, ... income and no chronic health conditions are more likely ... study in the October issue of The ... study of its kind, researchers from Portland State University, ...
... added benefits to improve care and quality ... health conditions-, SAN ANTONIO, Texas, Oct. 27 ... period which begins November 15th, Care,Improvement Plus today ... Plan,(SNP) offerings for chronically ill Medicare beneficiaries in ...
... the Johns Hopkins Bloomberg School of Public Health have ... older Americans to understand patterns of disability and aging. ... National Institutes of Health, is expected to award approximately ... and implement the new survey. The study will include ...
... PHILADELPHIA Edith P. Mitchell, M.D., clinical professor, Department ... Jefferson University and associate director of Diversity Programs for ... with a ,Tree of Life, award from The Wellness ... organization. , The Tree of Life award ...
Cached Medicine News:Health News:Air Methods Receives $17 Million Contract from Sikorsky Aircraft Company 2Health News:Springer adds Journal of Neurodevelopmental Disorders to biomedical journal portfolio 2Health News:Study reveals factors of exceptional health in old age 2Health News:Care Improvement Plus Launches 2009 Benefits in Texas 2Health News:Bloomberg School of Public Health to lead nationwide aging study 2Health News:Jefferson doctor receives Tree of Life award 2Health News:Jefferson doctor receives Tree of Life award 3
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of CRP in serum....
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative determination of apolipoprotein B (apo B) in serum and plasma....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: